Breast Cancer Clinical Trial
Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups
Summary
The Compass Course (CC) is a group intervention designed for individuals with Breast Cancer. Over the course of 8 face-to-face group sessions, the CC is designed to help participants reclaim a sense of self-grounded purpose in daily life, defined as intentional use of time and energy in ways that align with one's values, strengths, and sources of personal meaning (e.g., inner compass) in the moments that compose a day. Because of COVID-19, in-person groups are discouraged and so we need to identify new ways to provide group-based interventions that are feasible and efficacious.
Eligibility Criteria
Inclusion Criteria:
Able to attend intervention sessions for 9 weeks on Monday or Tuesday afternoons (4:30 - 6:30 pm) starting Monday, April 5, 2021
25 years of age or older
Completed chemotherapy and/or radiation treatment for Stage 0, 1, 2, or 3 breast cancer at least 2 months prior to participating in the Compass Course intervention
English speaking
Graduated from high school
Able to see, hear, speak (with or without assistive devices)
Able to provide own transportation to sessions
Willing and able to commit to attend all 8 intervention sessions
Access to computer or tablet and adequate internet connection to participate in video conference
Exclusion Criteria:
Stage 4 breast cancer or any other cancer
Actively receiving chemotherapy or radiation treatments for cancer. (However, patients may be on Herceptin and/or endocrine treatment and participate in the study.)
History of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning
Any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Minneapolis Minnesota, 55447, United States
How clear is this clinincal trial information?
